Literature DB >> 20702713

Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes.

Marta Valenza1, Valerio Leoni, Joanna M Karasinska, Lara Petricca, Jianjia Fan, Jeffrey Carroll, Mahmoud A Pouladi, Elisa Fossale, Huu Phuc Nguyen, Olaf Riess, Marcy MacDonald, Cheryl Wellington, Stefano DiDonato, Michael Hayden, Elena Cattaneo.   

Abstract

Brain cholesterol, which is synthesized locally, is a major component of myelin and cell membranes and participates in neuronal functions, such as membrane trafficking, signal transduction, neurotransmitter release, and synaptogenesis. Here we show that brain cholesterol biosynthesis is reduced in multiple transgenic and knock-in Huntington's disease (HD) rodent models, arguably dependent on deficits in mutant astrocytes. Mice carrying a progressively increased number of CAG repeats show a more evident reduction in cholesterol biosynthesis. In postnatal life, the cholesterol-dependent activities of neurons mainly rely on the transport of cholesterol from astrocytes on ApoE-containing particles. Our data show that mRNA levels of cholesterol biosynthesis and efflux genes are severely reduced in primary HD astrocytes, along with impaired cellular production and secretion of ApoE. Consistently, in CSF of HD mice, ApoE is mostly associated with smaller lipoproteins, indicating reduced cholesterol transport on ApoE-containing lipoproteins circulating in the HD brain. These findings indicate that cholesterol defect is robustly marked in HD animals, implying that strategies aimed at selectively modulating brain cholesterol metabolism might be of therapeutic significance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20702713      PMCID: PMC3842469          DOI: 10.1523/JNEUROSCI.0917-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  25 in total

1.  CNS synaptogenesis promoted by glia-derived cholesterol.

Authors:  D H Mauch; K Nägler; S Schumacher; C Göritz; E C Müller; A Otto; F W Pfrieger
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

2.  Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?

Authors:  Frank W Pfrieger
Journal:  Bioessays       Date:  2003-01       Impact factor: 4.345

Review 3.  Mouse models of Huntington's disease.

Authors:  Liliana B Menalled; Marie-Françoise Chesselet
Journal:  Trends Pharmacol Sci       Date:  2002-01       Impact factor: 14.819

4.  Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles.

Authors:  C Thiele; M J Hannah; F Fahrenholz; W B Huttner
Journal:  Nat Cell Biol       Date:  2000-01       Impact factor: 28.824

5.  Transgenic rat model of Huntington's disease.

Authors:  Stephan von Hörsten; Ina Schmitt; Huu Phuc Nguyen; Carsten Holzmann; Thorsten Schmidt; Thomas Walther; Michael Bader; Reinhard Pabst; Philipp Kobbe; Jana Krotova; Detlef Stiller; Ants Kask; Annika Vaarmann; Silvia Rathke-Hartlieb; Jörg B Schulz; Ute Grasshoff; Ingrid Bauer; Ana Maria Menezes Vieira-Saecker; Martin Paul; Lesley Jones; Katrin S Lindenberg; Bernhard Landwehrmeyer; Andreas Bauer; Xiao-Jiang Li; Olaf Riess
Journal:  Hum Mol Genet       Date:  2003-03-15       Impact factor: 6.150

Review 6.  Molecular mechanisms and potential therapeutical targets in Huntington's disease.

Authors:  Chiara Zuccato; Marta Valenza; Elena Cattaneo
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

7.  Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function.

Authors:  Joanna M Karasinska; Franz Rinninger; Dieter Lütjohann; Piers Ruddle; Sonia Franciosi; Janine K Kruit; Roshni R Singaraja; Veronica Hirsch-Reinshagen; Jianjia Fan; Liam R Brunham; Nagat Bissada; Rajasekhar Ramakrishnan; Cheryl L Wellington; John S Parks; Michael R Hayden
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

Review 8.  Brain cholesterol: long secret life behind a barrier.

Authors:  Ingemar Björkhem; Steve Meaney
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-02-05       Impact factor: 8.311

9.  Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease.

Authors:  Valerio Leoni; Caterina Mariotti; Sarah J Tabrizi; Marta Valenza; Edward J Wild; Susie M D Henley; Nicola Z Hobbs; Maria Luisa Mandelli; Marina Grisoli; Ingemar Björkhem; Elena Cattaneo; Stefano Di Donato
Journal:  Brain       Date:  2008-09-04       Impact factor: 13.501

10.  Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses.

Authors:  Simonetta Sipione; Dorotea Rigamonti; Marta Valenza; Chiara Zuccato; Luciano Conti; Joel Pritchard; Charles Kooperberg; James M Olson; Elena Cattaneo
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

View more
  45 in total

1.  Neuroprotection and brain cholesterol biosynthesis in Huntington's disease.

Authors:  Marta Valenza; Elena Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-31       Impact factor: 11.205

2.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

Review 3.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

4.  Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.

Authors:  Eugenia Trushina; Christie A Canaria; Do-Yup Lee; Cynthia T McMurray
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

5.  Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

Authors:  Zhongmin Xiang; Marta Valenza; Libin Cui; Valerio Leoni; Hyun-Kyung Jeong; Elisa Brilli; Jiangyang Zhang; Qi Peng; Wenzhen Duan; Steven A Reeves; Elena Cattaneo; Dimitri Krainc
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

Review 6.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

7.  Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.

Authors:  Janett Eckmann; Laura E Clemens; Schamim H Eckert; Stephanie Hagl; Libo Yu-Taeger; Thierry Bordet; Rebecca M Pruss; Walter E Muller; Kristina Leuner; Huu P Nguyen; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2014-03-18       Impact factor: 5.590

8.  Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.

Authors:  Surya A Reis; Morgan N Thompson; Jong-Min Lee; Elisa Fossale; Hyung-Hwan Kim; James K Liao; Michael A Moskowitz; Stanley Y Shaw; Linda Dong; Stephen J Haggarty; Marcy E MacDonald; Ihn Sik Seong
Journal:  Hum Mol Genet       Date:  2011-03-29       Impact factor: 6.150

Review 9.  Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk.

Authors:  Sreedevi Raman; Nicholas Brookhouser; David A Brafman
Journal:  Neurobiol Dis       Date:  2020-02-05       Impact factor: 5.996

10.  Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.

Authors:  Lydie Boussicault; Anne-Sophie Hérard; Noel Calingasan; Fanny Petit; Carole Malgorn; Nicolas Merienne; Caroline Jan; Marie-Claude Gaillard; Rodrigo Lerchundi; Luis F Barros; Carole Escartin; Thierry Delzescaux; Jean Mariani; Philippe Hantraye; M Flint Beal; Emmanuel Brouillet; Céline Véga; Gilles Bonvento
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.